



## Testimony of

**Charles Maresca**  
**Director of Interagency Affairs**  
**Office of Advocacy**  
**U.S. Small Business Administration**

*United States Senate*  
*Committee on Small Business and Entrepreneurship*

**Date:** April 5, 2019  
**Time:** 1:00 P.M.  
**Location:** Performing Arts Building Auditorium  
Hillsborough Community College, Ybor City  
Campus  
2112 N. 15<sup>th</sup> Street  
Tampa, FL  
**Topic:** Keeping Small Premium Cigar Businesses  
Rolling

Chairman Rubio, Ranking Member Cardin, Members of the Committee, I am honored to be here today on behalf of the U.S. Small Business Administration (SBA) Office of Advocacy (Advocacy) to present testimony to you about the Food and Drug Administration's (FDA) regulation of premium cigars.

As the Director of Interagency Affairs, I manage a team of attorneys who work with federal government agencies during the rulemaking process to reduce regulatory burdens on small businesses and to implement the requirements of the Regulatory Flexibility Act (RFA). The RFA requires federal agencies to consider the effects of their proposed rules on small businesses and other small entities, including small governments and small nonprofits. Advocacy is an independent office within the SBA that speaks on behalf of the small business community before federal agencies, Congress, and the White House. The views in my testimony do not necessarily reflect the views of the Administration or the SBA, and this statement has not been circulated to the Office of Management and Budget for clearance.

### **Advocacy's Involvement in the Regulation of Premium Cigars**

The Family Smoking Prevention and Tobacco Control Act was signed into law in 2009; it amended the Federal Food, Drug, and Cosmetic Act and gives FDA the power to regulate "all cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco" and "any other tobacco products that the Secretary by regulation deems to be subject to this subchapter."<sup>1</sup> On April 24, 2014, FDA issued a proposed rule (the "Deeming Rule") that would deem formerly unregulated or uncovered products subject to FDA regulation, including premium cigars.<sup>2</sup> The proposed rule subjected newly covered products to regulatory requirements applicable to cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco. These requirements included general controls, health warnings, and sales and marketing restrictions. Additionally, the proposed rule required a previously uncovered product to be subject to FDA premarket authorization before being marketed in the United States if the product was "new." A "new" tobacco product was one that was not marketed as of February 15, 2007. Manufacturers of such products must submit either a Premarket Tobacco Application or

---

<sup>1</sup> 21 U.S.C. § 387a(b) (2009).

<sup>2</sup> Deeming Tobacco Products to be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 79 Fed. Reg. 23,142 (proposed Apr. 25, 2014), (to be codified at 21 C.F.R. pts. 1100,1140, & 1143).



a Substantial Equivalence (SE) Report to or request a Minor Modification Exemption from FDA.

On June 11, 2014, Advocacy submitted a comment letter on the Deeming Rule to FDA, addressing the agency's Initial Regulatory Flexibility Analysis (IRFA) under the RFA.<sup>3</sup> An IRFA is required to contain: (1) a description of the reasons why action by the agency is being considered; (2) a succinct statement of the objectives of, and legal basis for, the proposed rule; (3) a description of and, where feasible, an estimate of the number of small entities to which the proposed rule will apply; (4) a description of the projected reporting, recordkeeping and other compliance requirements of the proposed rule, including an estimate of the classes of small entities which will be subject to the requirement and the type of professional skills necessary for preparation of the report or record; (5) an identification, to the extent practicable, of all relevant federal rules which may duplicate, overlap, or conflict with the proposed rule; and (6) a description of any significant alternatives to the proposed rule which accomplish the stated objectives of the applicable statutes and which minimize any significant economic impact of the proposed rule on small entities.<sup>4</sup> In its letter, Advocacy stated that FDA's IRFA was deficient because it neither adequately: (1) described the impacts on all of the types of newly covered small entities, nor (2) explained significant alternatives that might reduce those impacts. Advocacy suggested that FDA publish a Supplemental IRFA for public comment before proceeding with the Deeming Rule.

FDA did not publish a Supplemental IRFA, and on May 10, 2016, the Deeming Rule became final. Notably, one alternative FDA had considered in the proposed rule was the possible exemption of premium cigars from the rule. However, FDA found "no appropriate public health justification to exclude premium cigars;" therefore, premium cigars were not exempted from the final Deeming Rule.<sup>5</sup>

On July 28, 2017, FDA announced a new comprehensive plan for regulating tobacco and nicotine.<sup>6</sup> To that end, on March 26, 2018, it published an advance notice of proposed rulemaking entitled *Regulation of Premium Cigars*, requesting more

---

<sup>3</sup> The comment letter is attached as Appendix 1.

<sup>4</sup> 5 U.S.C. § 603 (2019).

<sup>5</sup> Deeming Tobacco Products to Be Subject to the Federal Food, Drug and Cosmetic Act, as Amended by the Family Smoking Prevention and Control Act; Restriction on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products; Final Rule, 81 Fed. Reg. 28,974, 29,020 (May 10, 2016) (to be codified at 21 C.F.R. pts. 1100, 1140, & 1143).

<sup>6</sup> Food & Drug Admin., *News Release: FDA Announces Comprehensive Regulatory Plan to Shift Trajectory of Tobacco-Related Disease, Death* (July 28, 2017), <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm568923.htm>.



information related to the regulation of premium cigars.<sup>7</sup> Specifically, FDA requested comments related to the definition of premium cigars, the use patterns of premium cigars, and the public health considerations associated with premium cigars.<sup>8</sup>

On July 25, 2018, Advocacy submitted a comment letter on the advanced notice of proposed rulemaking to FDA.<sup>9</sup> As we stated in our 2014 comment letter on the Deeming Rule, Advocacy again urged FDA to include a more robust economic analysis of the rule's impact on small businesses and a description of significant alternatives that would minimize that impact when it publishes an IRFA for its proposed rule on the regulation of premium cigars. Advocacy also resubmitted its 2014 Deeming Rule comment letter to FDA. To date, FDA has not published a notice of proposed rulemaking for the regulation of premium cigars. Advocacy's request is consistent with the Congressional intent underlying the RFA, that when adopting regulations to protect the health, safety, and economic welfare of the nation, federal agencies should seek to achieve statutory goals as effectively as possible without imposing unnecessary burdens on the public.

Between June 2017 and September 2018, Advocacy hosted 33 regional roundtables in 22 states to hear from small businesses about the regulatory issues with which they are most concerned. We hosted three such roundtables in Florida, including one here in Tampa. Advocacy heard compelling stories from small business owners in the premium cigar industry at many of those roundtables. In December 2018 Advocacy published its progress report about the issues discussed at those regional roundtables. I am also pleased to announce that Advocacy's RFA Annual Report for fiscal year 2018 was delivered to Congress this week.

### **The Deeming Rule's Effect on Premium Cigars**

Attached to this testimony is a thumbnail sketch of the premium cigar industry.<sup>10</sup> Advocacy believes that small businesses dominate the premium cigar industry. There are at least 50 manufacturers of premium cigars across 19 states or more, all small businesses.<sup>11</sup> Indeed, over 20 of those manufacturers are in Florida alone. Additionally,

---

<sup>7</sup> Regulation of Premium Cigars, 83 Fed. Reg. 12,901 (proposed Mar. 26, 2018), (to be codified at 21 C.F.R. pts. 1100, 1140, & 1143).

<sup>8</sup> *Id.* at 12,903.

<sup>9</sup> The comment letter is attached as Appendix 2.

<sup>10</sup> See Appendix 3.

<sup>11</sup> In its Final Regulatory Flexibility Analysis (FRFA) for the Deeming Rule, FDA states that according to the Alcohol and Tobacco Tax and Trade Bureau (TTB) there were 113 domestic cigar manufacturers in 2013. The TTB does not differentiate between premium and non-premium cigar manufacturers for tax purposes. See also Appendix 3.



there are over 3,000 retailers of premium cigars located in all 50 states, some of which also roll their own cigars and are considered manufacturers under FDA's Deeming Rule.

According to FDA's own estimates, the Deeming Rule's compliance costs will have significant impacts on small businesses. Specifically, FDA states that some "low-volume cigar" manufacturers may end their domestic operations entirely.<sup>12</sup> Premium cigar manufacturers are the very definition of "low-volume" cigar manufacturers. Their cigars are handmade and labor intensive, manufactured by the hundreds per day as opposed to the thousands an hour for mass-marketed, machine-made cigars.

For a small business cigar manufacturer, FDA estimates compliance costs to be \$278,000 to \$397,000 in the first year, \$292,000 to \$411,000 in the second year, and \$235,000 to \$257,000 in the third year.<sup>13</sup> Although many small businesses have argued that the costs will be much higher than FDA's estimates, the agency's own numbers will prove to be too much for most small businesses to pay to continue to manufacture premium cigars. Included in those costs would be applying for premarket approval or completing an SE Report. An SE Report for cigars includes a detailed chemical analysis of: (1) the cigar itself, (2) the cigar band paper and ink, (3) the wood of the cigar box, and (4) the cellophane wrapper in which the cigars are wrapped. The premium cigar industry has argued that one SE Report could cost up to \$250,000.<sup>14</sup>

For manufacturers who cannot afford the Deeming Rule's compliance costs and are forced to shutter their factories, there will be thousands of employees who will no longer be employed. Cigar Rights of America estimates that there are approximately 35,000 jobs associated with the premium cigar industry, which includes manufacturing employees, retail employees, and other employees throughout the industry's supply chain.<sup>15</sup>

---

<sup>12</sup> Deeming Tobacco Products to be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations Restricting the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Product Packages and Advertisements FRFA, Docket No. FDA-2014-N-0189, at 70, available at <https://www.regulations.gov/document?D=FDA-2014-N-0189-83196>.

<sup>13</sup> *Id.* at 132.

<sup>14</sup> Comment Letter from Cigar Association of America, Inc. to FDA Division of Dockets Management RE: Docket No. FDA-2017-N-5095 (Feb. 5, 2018), at 17, available at <https://www.regulations.gov/contentStreamer?documentId=FDA-2017-N-5095-0032&attachmentNumber=1&contentType=pdf>.

<sup>15</sup> Comment Letter from Norton Rose Fulbright, US LLP to The Honorable Scott Gottlieb RE: Comment of the International Premium Cigar and Pipe Retailers Association and Cigar Rights of America on Docket No. FDA-2017-N-6107, Regulation of Premium Cigars (July 25, 2018), at 74, available at <https://www.regulations.gov/contentStreamer?documentId=FDA-2017-N-6107-8796&attachmentNumber=1&contentType=pdf>.



U.S. Small Business  
Administration

## **Conclusion**

While FDA has stated the objectives of the deeming rule under the authorizing statute, it is still required by the RFA to consider significant alternatives to the rule that would minimize the impact on small businesses. Advocacy and small businesses are extremely concerned about the Deeming Rule's effects on small premium cigar businesses. Indeed, Advocacy made its concerns known to FDA in 2014, and those concerns have not changed. FDA must conduct a more robust economic analysis on the rule's impacts on small businesses, specific to the affected premium cigar industry, and consider significant alternatives to those impacts to accomplish the agency's stated objective while keeping small premium cigar manufactures and retailers in business. I would be happy to answer any questions you may have.



U.S. Small Business  
Administration

Created by Congress in 1976, the Office of Advocacy of the U.S. Small Business Administration (SBA) is an independent voice for small business within the federal government. The Chief Counsel for Advocacy, who is appointed by the President and confirmed by the U.S. Senate, directs the office. The Chief Counsel advances the views, concerns, and interests of small business before Congress, the White House, federal agencies, federal courts, and state policy makers. Issues are identified through economic research, policy analyses, and small business outreach. The Chief Counsel's efforts are supported by offices in Washington, D.C., and by Regional Advocates. For more information about the Office of Advocacy, visit <http://www.sba.gov/advocacy>, or call (202) 205-6533.



## Appendix 1

SBA Office of Advocacy June 11, 2014, Comment Letter RE: Deeming Tobacco Products to Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act, Docket No. FDA-2014-N-0189



409 3<sup>rd</sup> Street SW / MC 3110 / Washington, DC 20416 /  
Ph 202-205-6533 / [advocacy.sba.gov](http://advocacy.sba.gov)





*Advocacy: the voice of small business in government*

June 11, 2014

VIA ELECTRONIC SUBMISSION

The Honorable Margaret A. Hamburg, M.D.  
Commissioner  
U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Room 2217  
Silver Spring, MD 20993  
<http://www.regulations.gov>

Re: Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act, Docket No. FDA-2014-N-0189

Dear Commissioner Hamburg:

The Office of Advocacy (Advocacy) offers the following comment to the Food and Drug Administration (FDA) in response to the above-referenced proposed rule issued on April 24, 2014.<sup>1</sup> The FDA issued the proposed rule to implement provisions of the Family Smoking Prevention and Tobacco Control Act of 2009 (Tobacco Control Act)<sup>2</sup>. Since the passage of the Tobacco Control Act, small businesses that manufacture or market tobacco products have been in contact with Advocacy in anticipation of this rulemaking. After the FDA promulgated this proposal, small business owners continued to contact and meet with Advocacy to convey feedback about the proposed rule. Based on input from small business stakeholders, Advocacy is concerned that the Initial Regulatory Flexibility Analysis (IRFA) contained in the proposed rule lacks essential information required under the Regulatory Flexibility Act (RFA)<sup>3</sup>. Specifically, the IRFA does not discuss the quantitative or qualitative costs of the proposed rule on many potentially affected small entities. Moreover, given the extent of the anticipated costs of this proposal, the IRFA does not adequately consider or explain significant alternatives which accomplish the stated FDA objectives while minimizing the significant economic impact of the proposal on small entities. For this reason, Advocacy recommends that the FDA republish for public comment a Supplemental IRFA before proceeding with this rulemaking.

<sup>1</sup> 79 Fed. Reg. 23,142 (April 25, 2014). Proposed rule available at: <https://www.federalregister.gov/articles/2014/04/25/2014-09491/deeming-tobacco-products-to-be-subject-to-the-federal-food-drug-and-cosmetic-act-as-amended-by-the>.

<sup>2</sup> 21 U.S. Code § 387a.

<sup>3</sup> 5 U.S.C. § 601 et seq.

## **Office of Advocacy**

Advocacy was established pursuant to Pub. L. 94-305 to represent the views of small entities before federal agencies and Congress. Advocacy is an independent office within SBA, so the views expressed by Advocacy do not necessarily reflect the views of the SBA or the Administration. The RFA, as amended by the Small Business Regulatory Enforcement Fairness Act (SBREFA),<sup>4</sup> gives small entities a voice in the rulemaking process. For all rules that are expected to have a significant economic impact on a substantial number of small entities, federal agencies are required by the RFA to assess the impact of the proposed rule on small business and to consider less burdensome alternatives.

The RFA requires agencies to give every appropriate consideration to comments provided by Advocacy. The agency must include, in any explanation or discussion accompanying the final rule's publication in the Federal Register, the agency's response to these written comments submitted by Advocacy on the proposed rule, unless the agency certifies that the public interest is not served by doing so.<sup>5</sup>

## **Background**

The Tobacco Control Act authorizes the FDA to regulate the manufacture, distribution, and marketing of tobacco products to "protect public health." The Tobacco Control Act provides that other tobacco-related products can be subject to FDA regulation if the agency deems them to be regulated products under a rulemaking process referred to as the "deeming regulation."

On April 24, 2014, the FDA Center for Tobacco Products issued a proposed rule that would deem formerly unregulated or uncovered products subject to FDA regulation, including premium cigars, e-cigarettes, and hookah tobacco. In the release, the FDA proposes and requests comment on an option where it would not deem (i.e., the agency would exempt) premium cigars. The FDA is considering this option because "it has been suggested that different kinds of cigars may have the potential for varying effects on public health, based on possible differences in their effects on dual use, youth initiation and frequency of use by youth and young adults."<sup>6</sup>

The deeming regulations would subject newly covered products to regulatory requirements currently only applicable to cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco. These requirements include general controls, health warnings, and sales and marketing restrictions. Additionally, under the proposal, a previously uncovered product would be subject to FDA premarket authorization before it may be marketed in the United States if the product is "new." A tobacco product is considered "new" if it was not being marketed as of February 15, 2007 (the "Grandfather Date") or if any modification has been made to the product that was on the market before the Grandfather Date. If the FDA treats a product as "new," the product manufacturer must submit to the FDA either a Premarket Tobacco Application, a Substantial Equivalence (SE) Report, or request a Minor Modification Exemption. For purposes of an SE report, a business must cite a predicate product that was commercially marketed as of the

---

<sup>4</sup> Pub. L. 104-121, Title II, 110 Stat. 857 (1996) (codified in various sections of 5 U.S.C. § 601 et seq.).

<sup>5</sup> 5 U.S.C. § 601 et seq.

<sup>6</sup> See proposed rule at page 8.

**Grandfather Date, and contain detailed information about the cited predicate product, including complete specifications, ingredient and component information, manufacturing information, and product testing data.**

**In the proposal, the FDA observes that “approximately 90 percent of domestic entities affected by this rule are estimated to be small.” The FDA estimates that upfront costs for small businesses will measure approximately \$390,000 - \$759,000 and that annual compliance costs for small businesses will measure approximately \$450,000 - \$541,000.<sup>7</sup> The FDA notes that the annual costs of the proposed rule are expected to be greater than 10 percent of sales for small manufacturers / producers. However, the FDA’s Preliminary Regulatory Impact Analysis (PRIA) and IRFA<sup>8</sup> suggest that there is uncertainty around these cost estimates. In several portions of its analysis, the FDA concedes that it has not accurately quantified all of the costs and burdens associated with extending its authority to regulate previously uncovered products.<sup>9</sup>**

**Since the passage of the Tobacco Control Act, small businesses that manufacture or market previously uncovered products have been in contact with Advocacy in anticipation of this rulemaking. After the FDA issued the proposal, small business owners have continued to contact Advocacy to convey concerns related specifically to the proposed rule. Advocacy has heard from small businesses that market and sell tobacco products as well as previously uncovered products, small businesses in the “little cigar” industry, small businesses in the “premium cigar” industry, small businesses in the e-cigarette industry, and small businesses in the hookah industry.**

#### **The Proposed Rule’s IRFA is Deficient**

**Because it does not adequately describe the impacts on all types of newly covered small entities and because it does not adequately explain significant alternatives that might reduce those impacts, Advocacy believes that the IRFA contained in the proposed rule is deficient, and for this reason, the FDA should republish a Supplemental IRFA for additional public comment before proceeding with this rulemaking. Under the RFA, an IRFA must contain: (1) a description of the reasons why the regulatory action is being taken; (2) the objectives and legal basis for the proposed regulation; (3) a description and estimated number of regulated small entities; (4) a description and estimate of compliance requirements, including any differential for different categories of small entities; (5) identification of duplication, overlap, and conflict with other rules and regulations; and (6) a description of significant alternatives to the rule.<sup>10</sup> Advocacy is concerned that because the proposed rule’s IRFA is deficient, the public has not been adequately informed about the possible impact of the proposal on small entities and whether there are less burdensome significant alternatives to the proposed rule that would meet the FDA’s objectives.**

**Given the scope of the proposal and the number of small entities that would be impacted by it, the IRFA should include more data and analysis to provide the public with sufficient information on the economic impact of the proposed rule. However, the IRFA contained in the proposed rule**

---

<sup>7</sup> See proposed rule at page 191.

<sup>8</sup> PRIA and IRFA available at:

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/UCM394933.pdf>.

<sup>9</sup> See, e.g., PRIA at pages 7, 12, 25, and 41.

<sup>10</sup> 5 USC § 603.

does not adequately describe and estimate the costs the proposal would impose on small entities by both omitting a substantive discussion of costs that accrue to products with many small entities and understating compliance costs. As described above, the FDA does not quantify many of the costs and burdens associated with the proposed rule in the IRFA even for product categories where the agency estimates there are a sizeable number of small manufacturers. Instead, the FDA presents data and analysis only for cigar manufacturers and uses a limited dataset that does not measure burgeoning marketplaces such as online sales.

Many small businesses have expressed concern to Advocacy regarding costs related to premarket submissions that the proposed rule would require. These small businesses have explained to Advocacy that the cost estimates in the IRFA may be understated because the FDA does not account for differences in the way that small business will comply with the proposed rule. As an example, the FDA does not recognize that the proposal may be disproportionately burdensome to small entities that do not have the legal resources of larger businesses.

Additionally, many small businesses have told Advocacy that they will have trouble utilizing the less burdensome SE premarket submission process. Because businesses in industries for newly covered products would not be able to obtain marketing orders as many of these industries, such as e-cigarettes, were not in existence as of the Grandfather Date, or they rely on proprietary technologies. Small businesses have even confided to Advocacy that the costs associated with the proposal's premarket submission requirements could force many of them to exit the market and cease operating.

Taking into account the potentially extensive costs of the proposal, the IRFA does not fully consider significant alternatives which accomplish the stated FDA objectives and which minimize the significant economic impact of the proposal on small entities. All of the alternatives currently considered in the IRFA would only make marginal changes to the overall compliance costs to small entities, such as exempting products from labeling changes. Therefore, Advocacy encourages the FDA to further consider alternatives that may be able to more greatly decrease the regulatory burden on small business while still allowing the FDA to meet its regulatory goals.

The RFA provides guidance on this issue and it instructs agencies that when faced with economic impacts as significant as those estimated by the FDA, agencies should consider alternatives such as: (1) the establishment of different compliance or reporting requirements for small entities or timetables that take into account the resources available to small entities; (2) clarification, consolidation, or simplification of compliance and reporting requirements for small entities; (3) use of performance rather than design standards; and (4) exemption for certain or all small entities from coverage of the rule, in whole or in part.<sup>11</sup> Advocacy believes that all of these categories of alternatives would be relevant and useful to consider as a part of this rulemaking.

Notably, the proposed rule considers some of these alternatives for one specific product category: premium cigars. In the proposal, the FDA provides detailed data showing why the agency is considering this alternative and the cost savings that exempting premium cigars would yield. While Advocacy appreciates this example of an alternative that could meet regulatory goals while significantly reducing regulatory burdens, the FDA however does not provide an analysis related

---

<sup>11</sup> See 5 U.S.C. § 603(c).

to this alternative in the IRFA for premium cigars or any other product. Advocacy is unsure of why the FDA would not consider this significant alternative in the proposal's IRFA. Further, Advocacy is concerned that the FDA did not discuss and consider other alternatives in the IRFA that would yield similar significant cost savings as exempting premium cigars would, and that the agency did not perform a similar level of analysis on the alternatives listed in the IRFA as the agency did do elsewhere in the rule related to premium cigars. Advocacy recommends that FDA extend the analysis done on premium cigars to more product types so that the FDA can ensure that it is proposing the most effective and efficient regulation possible.

### **Recommendations**

Advocacy recommends that the FDA revise the IRFA to provide a more accurate description of the costs of the proposed rule by including a quantitative analysis of all product categories that are manufactured or marketed by small businesses. Specifically, although the FDA notes in the proposed rule that it expects the proposal to directly impact small businesses that market or manufacture cigars, pipe tobacco, hookah, and e-cigarettes, the FDA does not provide a detailed analysis of the potential impact on many of the small entities for newly covered products. As described above, the FDA provides a detailed analysis for only one alternative – not deeming premium cigars – that would yield significant cost savings for certain small businesses. Advocacy encourages the FDA to apply this analysis elsewhere in the IRFA so that not deeming other product categories can be considered and comprehensively discussed. The FDA should develop an alternative to consider regarding not deeming other “premium” products that are similarly marketed, designed, and used as premium cigars. The FDA should also provide additional data and analysis to illustrate why the benefits of deeming some of these products outweigh the substantial costs.

Advocacy also believes that even if an alternative is discussed elsewhere in the proposed rule, for purposes of the RFA analysis, it should be discussed in the IRFA portion of the proposal to allow for more substantive public comment and improved transparency around the FDA's analysis. Moreover, to improve the quality of comments received by the public and to ensure a comprehensive review under the RFA where FDA chooses to reject an alternative, the FDA should provide a policy or economic justification as to why it did not adopt each particular alternative considered.

Advocacy also recommends that the FDA should take into consideration small business stakeholders' suggested alternatives to minimize the proposed rule's potential impact. Small business representatives in contact with Advocacy observe that the FDA could still achieve its stated purposes for the premarket submission process in the deeming proposal through the use and enforcement of statutes and regulations already in effect. As an example, small business representatives note that under 21 U.S.C. § 387d(a)(1) and § 387d (c), manufacturers and importers of regulated tobacco products are required to submit (and update) specific information about the ingredients in each marketed product. Similarly, 21 U.S.C. § 387e mandates the registration of all domestic tobacco product manufacturing establishments and product listings for all regulated tobacco products manufactured at such establishments. Advocacy encourages the FDA to review and discuss statutes and regulations currently in effect as suggested by small

**business stakeholders that may already achieve the purposes of the premarket submission process in the deeming proposal.**

**Finally, Advocacy would like the FDA to provide at least a 90-day comment period for the proposed rule given the large economic impact that it is estimated it will have on small business. Small business will need sufficient time to analyze the potential impact of this proposed rule.**

### **Conclusion**

**Advocacy is concerned that the FDA's proposed rule and IRFA lack essential information needed to properly inform the agency's decision making. Specifically, the IRFA does not adequately describe the costs of the proposed rule on small entities, and the IRFA does not set forth, consider, and discuss significant alternatives which accomplish the stated FDA objectives and which minimize the significant economic impact of the proposal on small entities. For this reason, Advocacy recommends that the FDA republish for public comment a Supplemental IRFA before proceeding with this rulemaking.**

**By republishing a Supplemental IRFA, small businesses will have more adequate data to assess the potential impact of the proposed rule. The FDA will further gain valuable insight into the effects of the proposed rule on small business and be more transparent in explaining and justifying the choices that it made in the proposal. Advocacy also believes that the FDA should take into consideration small business representatives' suggested alternatives that may minimize the proposed rule's potential impact.**

Advocacy is committed to helping the FDA comply with the RFA in the development of the proposed rule. Therefore, Advocacy stands ready to assist the FDA in the completion of a Supplemental IRFA. Advocacy looks forward to working with the FDA. If you have any questions or require additional information please contact me or Assistant Chief Counsel Dillon Taylor at (202) 401-9787 or by email at [Dillon.Taylor@sba.gov](mailto:Dillon.Taylor@sba.gov).

Sincerely,



Winslow Sargeant, Ph.D.  
Chief Counsel for Advocacy



Dillon Taylor  
Assistant Chief Counsel Advocacy

Copy to: The Honorable Howard Shelanski, Administrator  
Office of Information and Regulatory Affairs  
Office of Management and Budget



## Appendix 2

SBA Office of Advocacy July 25, 2018, Comment Letter RE: Regulation of Premium Cigars, Advanced Notice of Proposed Rulemaking, 83 Fed. Reg. 12901 (March 26, 2018) (Doc. No. FDA-2017-N-6107)



409 3<sup>rd</sup> Street SW / MC 3110 / Washington, DC 20416 /  
Ph 202-205-6533 / [advocacy.sba.gov](http://advocacy.sba.gov)





July 25, 2018

VIA ELECTRONIC SUBMISSION

The Honorable Scott Gottlieb, M.D.  
Commissioner  
U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993

**Re: Regulation of Premium Cigars, Advance Notice of Proposed Rulemaking, 83 Fed. Reg. 12901 (March 26, 2018) (Doc. No. FDA-2017-N-6107).**

Dear Commissioner Gottlieb:

On March 26, 2018, the Food and Drug Administration (FDA) published an advance notice of proposed rulemaking entitled: *Regulation of Premium Cigars*.<sup>1</sup> The U.S. Small Business Administration's Office of Advocacy (Advocacy) appreciates the FDA's solicitation for more information related to the regulation of premium cigars and welcomes the opportunity to provide input on behalf of small business stakeholders. Advocacy recommends the agency consider and explain all significant alternatives in order to minimize the significant economic impact of any proposal on small entities.

### **The Office of Advocacy**

Congress established Advocacy under Pub. L. 94-305 to represent the views of small entities before Federal agencies and Congress. Advocacy is an independent office within the U.S. Small Business Administration (SBA); as such the views expressed by Advocacy do not necessarily reflect the views of the SBA or the Administration. The Regulatory Flexibility Act (RFA),<sup>2</sup> as amended by the Small Business Regulatory Enforcement Fairness Act (SBREFA),<sup>3</sup> gives small entities a voice in the rulemaking process. For all rules that are expected to have a significant

<sup>1</sup> See Food and Drug Admin.; *Regulation of Premium Cigars*, Advance Notice of Proposed Rulemaking, 83 Fed. Reg. 12901 (March 26, 2018).

<sup>2</sup> See 5 U.S.C. § 601 et seq.

<sup>3</sup> See Pub. L. 104-121, Title II, 110 Stat. 857 (1996) (codified in various sections of 5 U.S.C. § 601 et seq.).



economic impact on a substantial number of small entities, federal agencies are required by the RFA to assess the impact of the proposed rule on small entities and to consider less burdensome alternatives.

## **Background**

On June 22, 2009 the Tobacco Control Act was enacted and provided the FDA with authority to regulate the manufacture, distribution, and marketing of tobacco products to “protect the public health.”<sup>4</sup> The Tobacco Control Act further provides that other tobacco-related products can be subject to regulation if the FDA deems them to be regulated products under a rulemaking process referred to as the “deeming regulation.”

On April 24, 2014 the FDA issued a proposed deeming regulation that would deem formerly unregulated or uncovered products subject to FDA regulation, including premium cigars.<sup>5</sup> On June 11, 2014, Advocacy submitted comments on the proposed rule, citing concerns that the proposed rule’s Initial Regulatory Flexibility Act Analysis (IRFA) did not adequately consider or explain significant alternatives which could accomplish the stated FDA objectives while minimizing the significant economic impact of the proposal on small entities.<sup>6</sup> A copy of the letter is attached. The deeming rule became final on May 10, 2016.<sup>7</sup> While one of the proposed rule’s options contained an exemption for premium cigars, the final rule ultimately included premium cigars within the scope of the final rule.<sup>8</sup> On July 28, 2017, the FDA announced a new comprehensive plan for regulating tobacco and nicotine.<sup>9</sup> Pursuant to these efforts, on March 26, 2018, the FDA published an advance notice of proposed rulemaking seeking additional information related to the regulation of premium cigars.

## **Small Businesses are Concerned about the Impacts of Premium Cigar Regulation**

In its June 11, 2014 letter, Advocacy voiced concerns the proposed deeming rule’s IRFA was deficient, and therefore the public had not been adequately informed about the possible impact of the proposal on small entities and whether there were less burdensome significant alternatives to the proposed rule that would meet the FDA’s objectives. Many of the small business concerns cited in Advocacy’s previous letter still remain – including concerns related to the cost of premarket submissions and the potentially extensive costs of complying with any regulatory proposal.

---

<sup>4</sup> See Tobacco Control Act of 2009 (Pub. L. 111-31) amending FD&C Act, § 901, 21 U.S.C. 387a.

<sup>5</sup> See 79 Fed. Reg. 23142 (April 25, 2014).

<sup>6</sup> See SBA Office of Advocacy, *Letter re: Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products*, Docket No. FDA-2014-N-0189 (June 11, 2014), <https://www.sba.gov/advocacy/61114-deeming-tobacco-products-be-subject-federal-food-drug-and-cosmetic-act-amended-family>.

<sup>7</sup> See 81 Fed. Reg. 28974 (May 10, 2016).

<sup>8</sup> See *id.* at 29020.

<sup>9</sup> See Food and Drug Admin., *News Release: FDA announces comprehensive regulatory plan to shift trajectory of tobacco-related disease, death* (July 28, 2017), <https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm568923.htm>.

### Advocacy's Recommendations

Advocacy expects that any regulation of the premium cigar industry under the deeming rule would include a more robust economic analysis of the rule's impact on small businesses, and a description of significant alternatives that would minimize that impact. As we pointed out in our 2014 letter, the Regulatory Flexibility Act itself provides guidance on alternatives that the FDA should consider as a minimum: (1) the establishment of different compliance or reporting requirements for small entities or timetables that take into account the resources available to small entities; (2) clarification, consolidation, or simplification of compliance and reporting requirements for small entities; (3) use of performance rather than design standards; and (4) exemption for certain or all small entities from coverage of the rule, in whole or in part.<sup>10</sup>

Advocacy is encouraged that FDA has taken this step to acquire information that it would need to evaluate these alternatives and the significant alternatives that have been put forward by small businesses in the industry. Advocacy expects that in any proposed rulemaking FDA will include a full analysis of all significant alternatives and a fully explained rationale for its preferred alternative.

### Conclusion

In response to the agency's notice, Advocacy submits the above comments and resubmits its previous comments to assist the agency as it prepares its proposed rulemaking and any related RFA analysis. Advocacy recommends that the agency consider and explain all significant alternatives in order to minimize the significant economic impact of any proposal on small entities. If you have any questions or require additional information please contact me or the Director of the Office of Interagency Affairs, Charles Maresca, at (202) 205-6978 or by email at [charles.maresca@sba.gov](mailto:charles.maresca@sba.gov).

Sincerely,



Major L. Clark, III  
Acting Chief Counsel  
Office of Advocacy  
U.S. Small Business Administration



Charles A. Maresca  
Director of the Office of Interagency Affairs  
Office of Advocacy  
U.S. Small Business Administration

---

<sup>10</sup> See 5 U.S.C. § 603(c).



*Advocacy: the voice of small business in government*

June 11, 2014

VIA ELECTRONIC SUBMISSION

The Honorable Margaret A. Hamburg, M.D.  
Commissioner  
U.S. Food and Drug Administration  
10903 New Hampshire Avenue  
Room 2217  
Silver Spring, MD 20993  
<http://www.regulations.gov>

Re: Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act, Docket No. FDA-2014-N-0189

Dear Commissioner Hamburg:

The Office of Advocacy (Advocacy) offers the following comment to the Food and Drug Administration (FDA) in response to the above-referenced proposed rule issued on April 24, 2014.<sup>1</sup> The FDA issued the proposed rule to implement provisions of the Family Smoking Prevention and Tobacco Control Act of 2009 (Tobacco Control Act)<sup>2</sup>. Since the passage of the Tobacco Control Act, small businesses that manufacture or market tobacco products have been in contact with Advocacy in anticipation of this rulemaking. After the FDA promulgated this proposal, small business owners continued to contact and meet with Advocacy to convey feedback about the proposed rule. Based on input from small business stakeholders, Advocacy is concerned that the Initial Regulatory Flexibility Analysis (IRFA) contained in the proposed rule lacks essential information required under the Regulatory Flexibility Act (RFA)<sup>3</sup>. Specifically, the IRFA does not discuss the quantitative or qualitative costs of the proposed rule on many potentially affected small entities. Moreover, given the extent of the anticipated costs of this proposal, the IRFA does not adequately consider or explain significant alternatives which accomplish the stated FDA objectives while minimizing the significant economic impact of the proposal on small entities. For this reason, Advocacy recommends that the FDA republish for public comment a Supplemental IRFA before proceeding with this rulemaking.

<sup>1</sup> 79 Fed. Reg. 23,142 (April 25, 2014). Proposed rule available at: <https://www.federalregister.gov/articles/2014/04/25/2014-09491/deeming-tobacco-products-to-be-subject-to-the-federal-food-drug-and-cosmetic-act-as-amended-by-the>.

<sup>2</sup> 21 U.S. Code § 387a.

<sup>3</sup> 5 U.S.C. § 601 et seq.

## **Office of Advocacy**

Advocacy was established pursuant to Pub. L. 94-305 to represent the views of small entities before federal agencies and Congress. Advocacy is an independent office within SBA, so the views expressed by Advocacy do not necessarily reflect the views of the SBA or the Administration. The RFA, as amended by the Small Business Regulatory Enforcement Fairness Act (SBREFA),<sup>4</sup> gives small entities a voice in the rulemaking process. For all rules that are expected to have a significant economic impact on a substantial number of small entities, federal agencies are required by the RFA to assess the impact of the proposed rule on small business and to consider less burdensome alternatives.

The RFA requires agencies to give every appropriate consideration to comments provided by Advocacy. The agency must include, in any explanation or discussion accompanying the final rule's publication in the Federal Register, the agency's response to these written comments submitted by Advocacy on the proposed rule, unless the agency certifies that the public interest is not served by doing so.<sup>5</sup>

## **Background**

The Tobacco Control Act authorizes the FDA to regulate the manufacture, distribution, and marketing of tobacco products to "protect public health." The Tobacco Control Act provides that other tobacco-related products can be subject to FDA regulation if the agency deems them to be regulated products under a rulemaking process referred to as the "deeming regulation."

On April 24, 2014, the FDA Center for Tobacco Products issued a proposed rule that would deem formerly unregulated or uncovered products subject to FDA regulation, including premium cigars, e-cigarettes, and hookah tobacco. In the release, the FDA proposes and requests comment on an option where it would not deem (i.e., the agency would exempt) premium cigars. The FDA is considering this option because "it has been suggested that different kinds of cigars may have the potential for varying effects on public health, based on possible differences in their effects on dual use, youth initiation and frequency of use by youth and young adults."<sup>6</sup>

The deeming regulations would subject newly covered products to regulatory requirements currently only applicable to cigarettes, cigarette tobacco, roll-your-own tobacco, and smokeless tobacco. These requirements include general controls, health warnings, and sales and marketing restrictions. Additionally, under the proposal, a previously uncovered product would be subject to FDA premarket authorization before it may be marketed in the United States if the product is "new." A tobacco product is considered "new" if it was not being marketed as of February 15, 2007 (the "Grandfather Date") or if any modification has been made to the product that was on the market before the Grandfather Date. If the FDA treats a product as "new," the product manufacturer must submit to the FDA either a Premarket Tobacco Application, a Substantial Equivalence (SE) Report, or request a Minor Modification Exemption. For purposes of an SE report, a business must cite a predicate product that was commercially marketed as of the

---

<sup>4</sup> Pub. L. 104-121, Title II, 110 Stat. 857 (1996) (codified in various sections of 5 U.S.C. § 601 et seq.).

<sup>5</sup> 5 U.S.C. § 601 et seq.

<sup>6</sup> See proposed rule at page 8.

**Grandfather Date, and contain detailed information about the cited predicate product, including complete specifications, ingredient and component information, manufacturing information, and product testing data.**

**In the proposal, the FDA observes that “approximately 90 percent of domestic entities affected by this rule are estimated to be small.” The FDA estimates that upfront costs for small businesses will measure approximately \$390,000 - \$759,000 and that annual compliance costs for small businesses will measure approximately \$450,000 - \$541,000.<sup>7</sup> The FDA notes that the annual costs of the proposed rule are expected to be greater than 10 percent of sales for small manufacturers / producers. However, the FDA’s Preliminary Regulatory Impact Analysis (PRIA) and IRFA<sup>8</sup> suggest that there is uncertainty around these cost estimates. In several portions of its analysis, the FDA concedes that it has not accurately quantified all of the costs and burdens associated with extending its authority to regulate previously uncovered products.<sup>9</sup>**

**Since the passage of the Tobacco Control Act, small businesses that manufacture or market previously uncovered products have been in contact with Advocacy in anticipation of this rulemaking. After the FDA issued the proposal, small business owners have continued to contact Advocacy to convey concerns related specifically to the proposed rule. Advocacy has heard from small businesses that market and sell tobacco products as well as previously uncovered products, small businesses in the “little cigar” industry, small businesses in the “premium cigar” industry, small businesses in the e-cigarette industry, and small businesses in the hookah industry.**

### **The Proposed Rule’s IRFA is Deficient**

**Because it does not adequately describe the impacts on all types of newly covered small entities and because it does not adequately explain significant alternatives that might reduce those impacts, Advocacy believes that the IRFA contained in the proposed rule is deficient, and for this reason, the FDA should republish a Supplemental IRFA for additional public comment before proceeding with this rulemaking. Under the RFA, an IRFA must contain: (1) a description of the reasons why the regulatory action is being taken; (2) the objectives and legal basis for the proposed regulation; (3) a description and estimated number of regulated small entities; (4) a description and estimate of compliance requirements, including any differential for different categories of small entities; (5) identification of duplication, overlap, and conflict with other rules and regulations; and (6) a description of significant alternatives to the rule.<sup>10</sup> Advocacy is concerned that because the proposed rule’s IRFA is deficient, the public has not been adequately informed about the possible impact of the proposal on small entities and whether there are less burdensome significant alternatives to the proposed rule that would meet the FDA’s objectives.**

**Given the scope of the proposal and the number of small entities that would be impacted by it, the IRFA should include more data and analysis to provide the public with sufficient information on the economic impact of the proposed rule. However, the IRFA contained in the proposed rule**

---

<sup>7</sup> See proposed rule at page 191.

<sup>8</sup> PRIA and IRFA available at:

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/UCM394933.pdf>.

<sup>9</sup> See, e.g., PRIA at pages 7, 12, 25, and 41.

<sup>10</sup> 5 USC § 603.

does not adequately describe and estimate the costs the proposal would impose on small entities by both omitting a substantive discussion of costs that accrue to products with many small entities and understating compliance costs. As described above, the FDA does not quantify many of the costs and burdens associated with the proposed rule in the IRFA even for product categories where the agency estimates there are a sizeable number of small manufacturers. Instead, the FDA presents data and analysis only for cigar manufacturers and uses a limited dataset that does not measure burgeoning marketplaces such as online sales.

Many small businesses have expressed concern to Advocacy regarding costs related to premarket submissions that the proposed rule would require. These small businesses have explained to Advocacy that the cost estimates in the IRFA may be understated because the FDA does not account for differences in the way that small business will comply with the proposed rule. As an example, the FDA does not recognize that the proposal may be disproportionately burdensome to small entities that do not have the legal resources of larger businesses.

Additionally, many small businesses have told Advocacy that they will have trouble utilizing the less burdensome SE premarket submission process. Because businesses in industries for newly covered products would not be able to obtain marketing orders as many of these industries, such as e-cigarettes, were not in existence as of the Grandfather Date, or they rely on proprietary technologies. Small businesses have even confided to Advocacy that the costs associated with the proposal's premarket submission requirements could force many of them to exit the market and cease operating.

Taking into account the potentially extensive costs of the proposal, the IRFA does not fully consider significant alternatives which accomplish the stated FDA objectives and which minimize the significant economic impact of the proposal on small entities. All of the alternatives currently considered in the IRFA would only make marginal changes to the overall compliance costs to small entities, such as exempting products from labeling changes. Therefore, Advocacy encourages the FDA to further consider alternatives that may be able to more greatly decrease the regulatory burden on small business while still allowing the FDA to meet its regulatory goals.

The RFA provides guidance on this issue and it instructs agencies that when faced with economic impacts as significant as those estimated by the FDA, agencies should consider alternatives such as: (1) the establishment of different compliance or reporting requirements for small entities or timetables that take into account the resources available to small entities; (2) clarification, consolidation, or simplification of compliance and reporting requirements for small entities; (3) use of performance rather than design standards; and (4) exemption for certain or all small entities from coverage of the rule, in whole or in part.<sup>11</sup> Advocacy believes that all of these categories of alternatives would be relevant and useful to consider as a part of this rulemaking.

Notably, the proposed rule considers some of these alternatives for one specific product category: premium cigars. In the proposal, the FDA provides detailed data showing why the agency is considering this alternative and the cost savings that exempting premium cigars would yield. While Advocacy appreciates this example of an alternative that could meet regulatory goals while significantly reducing regulatory burdens, the FDA however does not provide an analysis related

---

<sup>11</sup> See 5 U.S.C. § 603(c).

to this alternative in the IRFA for premium cigars or any other product. Advocacy is unsure of why the FDA would not consider this significant alternative in the proposal's IRFA. Further, Advocacy is concerned that the FDA did not discuss and consider other alternatives in the IRFA that would yield similar significant cost savings as exempting premium cigars would, and that the agency did not perform a similar level of analysis on the alternatives listed in the IRFA as the agency did do elsewhere in the rule related to premium cigars. Advocacy recommends that FDA extend the analysis done on premium cigars to more product types so that the FDA can ensure that it is proposing the most effective and efficient regulation possible.

### **Recommendations**

Advocacy recommends that the FDA revise the IRFA to provide a more accurate description of the costs of the proposed rule by including a quantitative analysis of all product categories that are manufactured or marketed by small businesses. Specifically, although the FDA notes in the proposed rule that it expects the proposal to directly impact small businesses that market or manufacture cigars, pipe tobacco, hookah, and e-cigarettes, the FDA does not provide a detailed analysis of the potential impact on many of the small entities for newly covered products. As described above, the FDA provides a detailed analysis for only one alternative – not deeming premium cigars – that would yield significant cost savings for certain small businesses. Advocacy encourages the FDA to apply this analysis elsewhere in the IRFA so that not deeming other product categories can be considered and comprehensively discussed. The FDA should develop an alternative to consider regarding not deeming other “premium” products that are similarly marketed, designed, and used as premium cigars. The FDA should also provide additional data and analysis to illustrate why the benefits of deeming some of these products outweigh the substantial costs.

Advocacy also believes that even if an alternative is discussed elsewhere in the proposed rule, for purposes of the RFA analysis, it should be discussed in the IRFA portion of the proposal to allow for more substantive public comment and improved transparency around the FDA's analysis. Moreover, to improve the quality of comments received by the public and to ensure a comprehensive review under the RFA where FDA chooses to reject an alternative, the FDA should provide a policy or economic justification as to why it did not adopt each particular alternative considered.

Advocacy also recommends that the FDA should take into consideration small business stakeholders' suggested alternatives to minimize the proposed rule's potential impact. Small business representatives in contact with Advocacy observe that the FDA could still achieve its stated purposes for the premarket submission process in the deeming proposal through the use and enforcement of statutes and regulations already in effect. As an example, small business representatives note that under 21 U.S.C. § 387d(a)(1) and § 387d (c), manufacturers and importers of regulated tobacco products are required to submit (and update) specific information about the ingredients in each marketed product. Similarly, 21 U.S.C. § 387e mandates the registration of all domestic tobacco product manufacturing establishments and product listings for all regulated tobacco products manufactured at such establishments. Advocacy encourages the FDA to review and discuss statutes and regulations currently in effect as suggested by small



**business stakeholders that may already achieve the purposes of the premarket submission process in the deeming proposal.**

**Finally, Advocacy would like the FDA to provide at least a 90-day comment period for the proposed rule given the large economic impact that it is estimated it will have on small business. Small business will need sufficient time to analyze the potential impact of this proposed rule.**

### **Conclusion**

**Advocacy is concerned that the FDA's proposed rule and IRFA lack essential information needed to properly inform the agency's decision making. Specifically, the IRFA does not adequately describe the costs of the proposed rule on small entities, and the IRFA does not set forth, consider, and discuss significant alternatives which accomplish the stated FDA objectives and which minimize the significant economic impact of the proposal on small entities. For this reason, Advocacy recommends that the FDA republish for public comment a Supplemental IRFA before proceeding with this rulemaking.**

**By republishing a Supplemental IRFA, small businesses will have more adequate data to assess the potential impact of the proposed rule. The FDA will further gain valuable insight into the effects of the proposed rule on small business and be more transparent in explaining and justifying the choices that it made in the proposal. Advocacy also believes that the FDA should take into consideration small business representatives' suggested alternatives that may minimize the proposed rule's potential impact.**

Advocacy is committed to helping the FDA comply with the RFA in the development of the proposed rule. Therefore, Advocacy stands ready to assist the FDA in the completion of a Supplemental IRFA. Advocacy looks forward to working with the FDA. If you have any questions or require additional information please contact me or Assistant Chief Counsel Dillon Taylor at (202) 401-9787 or by email at [Dillon.Taylor@sba.gov](mailto:Dillon.Taylor@sba.gov).

Sincerely,



Winslow Sargeant, Ph.D.  
Chief Counsel for Advocacy



Dillon Taylor  
Assistant Chief Counsel Advocacy

Copy to: The Honorable Howard Shelanski, Administrator  
Office of Information and Regulatory Affairs  
Office of Management and Budget



## Appendix 3

# Summary of the Premium Cigar Industry Prepared by SBA Office of Advocacy



409 3<sup>rd</sup> Street SW / MC 3110 / Washington, DC 20416 /  
Ph 202-205-6533 / [advocacy.sba.gov](https://advocacy.sba.gov)

## Summary of the Premium Cigar Industry Prepared by SBA Office of Advocacy

### Industry

The premium cigar industry includes retailers, manufacturers, distributors, importers, and growers. Direct effects of the rule are mostly on manufacturers and importers. However, many retailers are also manufacturers or importers.

Premium cigars represent a very small part of the tobacco industry.

- Large cigars are about 5% of all cigars and cigarettes produced in or imported to the U.S. by volume, and premium cigars are a fraction of large cigars.<sup>1</sup>
- Premium cigars make up less than 3% of the cigar market.<sup>2</sup>

The premium cigar industry is predominately made up of small businesses.

- According to Food and Drug Administration, most cigar manufacturers are small, operating from a single establishment.<sup>3</sup> The SBA size standard for tobacco manufacturing (NAICS 312230), an industry classification that includes all manufacturers of tobacco products such as cigarettes, cigars, and pipe tobacco, is 1,500 employees.<sup>4</sup> In the tobacco manufacturing industry, 93% of businesses are small. According to Census Bureau economic data, there are only 9 firms within the tobacco manufacturing industry with more than 500 employees.<sup>5</sup>
- The SBA size standard for tobacco stores (NAICS 453991) is \$7.5 million in average annual revenue. There are over 9,000 tobacco stores in the U.S., and 97% of them are small businesses.<sup>6</sup> According to industry, about a third of tobacco stores sell premium cigars, and many stores make their own premium cigars as well.<sup>7</sup>

---

<sup>1</sup> U.S. Department of the Treasury, Alcohol and Tobacco Tax and Trade Bureau, Statistical Report-Tobacco Products (Mar. 12, 2018), <https://ttb.gov/statistics/2018/201812tobacco.pdf>.

<sup>2</sup> *Id.* (premium cigar share estimated using the highest taxed subgroup of cigars). The TTB does not differentiate between premium and non-premium cigar manufacturers for tax purposes.

<sup>3</sup> Deeming Tobacco Products to be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations Restricting the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Product Packages and Advertisements, Final Regulatory Impact Analysis (May 2016), <https://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/UCM500254.pdf>.

<sup>4</sup> U.S. Small Business Administration, Small Business Size Standards Matched to North American Industry Classification System Codes (Oct. 1, 2017), <https://www.sba.gov/sites/default/files/2018-07/NAICS%202017%20Table%20of%20Size%20Standards.pdf>.

<sup>5</sup> U.S. Census Bureau, 2016 SUSB Annual Data Tables by Establishment Industry (Dec. 4, 2018), <https://www.census.gov/data/tables/2016/econ/susb/2016-susb-annual.html>.

<sup>6</sup> U.S. Census Bureau, 2012 SUSB Annual Data Tables by Establishment Industry (Oct. 3, 2016), <https://www.census.gov/data/tables/2012/econ/susb/2012-susb-annual.html>.

<sup>7</sup> Comments of J.C. Newman Cigar Company, Regulation of Premium Cigars (Jul. 25, 2018), <https://www.regulations.gov/document?D=FDA-2017-N-6107-8608>.

## **Economic Impacts**

Estimated compliance costs of the deeming rule could eclipse the total sales for many premium cigar manufacturers. Retailers that sell premium cigars will also be affected.

- Based on Dun & Bradstreet data, a report commissioned by Cigar Rights of America estimated the median annual revenue for cigar manufacturers to be \$252,580.<sup>8</sup> According to Census data, 28 tobacco manufacturers make less than \$1 million in annual revenue, and small tobacco stores average \$779,816 in annual revenue.<sup>9</sup>
- Total first-year cost of the rule for a typical small manufacturer or importer according to the FDA is: \$277,750-\$397,350.<sup>10</sup> Compliance costs for affected small tobacco store retailers that sell cigars, such as lost sales, were not quantified by FDA. However, to the extent that retailers also make premium cigars, it is likely that the new requirements will force them to cease manufacturing activity.

## **Affected Small Entities-Manufacturers**

Economic data from the Census Bureau covers the tobacco industry broadly and does not break out the cigar or premium cigar industries specifically. In the absence of specific Census data, Advocacy identified premium cigar manufacturers in the U.S. using media coverage of the industry and information provided by trade associations.<sup>11</sup> We found that:<sup>12</sup>

- There are at least 56 cigar manufacturers in the U.S.
- These manufacturers are located in 19 states, with over 20 located in Florida.
- Of these manufacturers, 49 are also retailers.

Nearly all the manufacturers we identified were small-scale operations with a single location.

---

<sup>8</sup> *The Public Health, Financial and Employment Impacts of Excluding Handmade Cigars from Coverage by FDA's Final Rule*, Magnum Economics (October 2018), [https://cigar-coop.com/wpcontent/uploads/2018/12/Magnum\\_Study.pdf](https://cigar-coop.com/wpcontent/uploads/2018/12/Magnum_Study.pdf).

<sup>9</sup> See footnote 6.

<sup>10</sup> See footnote 3.

<sup>11</sup> Gregory Mottola, *50 Factories in the U.S. That Still Make Cigars*, Cigar Aficionado (Jan. 31, 2019), <https://www.cigaraficionado.com/article/50-factories-in-the-u-s-that-still-make-cigars>.

<sup>12</sup> We removed one business from the *Cigar Aficionado* list that had exited manufacturing, one business that appeared to have closed, and one retailer that we could not confirm was also a manufacturer. One firm had three establishments listed, and we counted this as a single firm. We also added 11 additional manufacturers not included in the original list. Our list represents a lower bound on the number of cigar manufacturers in the U.S., as there are likely to be a number of manufacturers we did not locate.